Want to see SE:ALZ full AI Analyst Report?
Top Page
Alzinova AB
(ALZ)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.41
▼(-50.12% Downside)
Action:Reiterated
Date:09/18/26
The score is held down primarily by weak financial performance driven by persistent losses and ongoing cash burn, despite a strong low-debt balance sheet. Technicals also weigh on the score due to a clear downtrend and bearish momentum, while valuation is constrained by a negative P/E and lack of dividend yield.
Positive Factors
Low leverage
Minimal debt and extremely low leverage reduce financial risk while preserving flexibility to fund research, pursue partnerships, or withstand development delays. This balance-sheet structure is supportive over the next several quarters because limited debt service avoids additional pressure on already negative operating cash flow.
Negative Factors
Persistent operating losses
Deeply negative operating profit and net income show that the company remains far from breakeven. Continued losses can consume the capital base, constrain investment choices, and increase dependence on successful clinical progress or external funding before sustainable earnings are possible.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Minimal debt and extremely low leverage reduce financial risk while preserving flexibility to fund research, pursue partnerships, or withstand development delays. This balance-sheet structure is supportive over the next several quarters because limited debt service avoids additional pressure on already negative operating cash flow.
Read all positive factors
Alzinova AB (ALZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr89.86M
Dividend YieldN/A
Average Volume (3M)2.11M
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-100.00%
EPS Growth20.96%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding202,640,560
10 Day Avg. Volume3,200,783
30 Day Avg. Volume2,109,076
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Alzinova AB Business Overview & Revenue Model
Company Description
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for ...
How the Company Makes Money
Alzinova AB’s primary economic model is typical of early-stage biotechnology companies focused on drug development: it seeks to create shareholder value and potential future revenues by advancing proprietary drug candidates through preclinical and...
Alzinova AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.98M | 0.00 | 30.00K | 270.00K | 16.63M | 17.32M |
| Gross Profit | 15.05M | 26.55M | 16.81M | 19.87M | 33.27M | 34.64M |
| EBITDA | -25.63M | -25.85M | -20.32M | 42.00K | -13.07M | -7.52M |
| Net Income | -24.29M | -26.27M | -20.55M | -16.48M | -13.07M | -7.58M |
Balance Sheet | ||||||
| Total Assets | 163.57M | 143.43M | 133.23M | 123.19M | 111.62M | 91.69M |
| Cash, Cash Equivalents and Short-Term Investments | 13.31M | 319.00K | 15.50M | 22.03M | 32.04M | 28.84M |
| Total Debt | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Total Liabilities | 7.60M | 21.47M | 9.40M | 9.33M | 6.09M | 3.22M |
| Stockholders Equity | 155.97M | 121.96M | 123.82M | 113.86M | 105.53M | 88.47M |
Cash Flow | ||||||
| Free Cash Flow | -34.60M | -39.58M | -37.05M | -34.82M | -26.95M | -27.14M |
| Operating Cash Flow | -23.75M | -13.03M | -20.27M | -15.21M | -10.31M | -9.82M |
| Investing Cash Flow | -19.92M | -26.55M | -16.78M | -19.60M | -16.63M | -17.32M |
| Financing Cash Flow | 45.47M | 24.41M | 30.52M | 24.80M | 30.15M | 0.00 |
Alzinova AB Technical Analysis
Negative
0.82
Price Trends
0.81
Negative
0.65
Negative
0.74
Negative
Market Momentum
-0.10
Positive
27.99
Positive
2.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZ, the sentiment is Negative. The current price of 0.82 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.81, and above the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 27.99 is Positive, neither overbought nor oversold. The STOCH value of 2.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZ.
Alzinova AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr28.22B | 272.77 | 5.18% | 0.66% | -46.09% | -90.13% | |
64 Neutral | kr1.41B | 7.47 | 29.71% | ― | 24.98% | -31.44% | |
52 Neutral | kr266.79M | -2.67 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.11B | 51.98 | 65.99% | ― | ― | ― | |
46 Neutral | kr89.86M | -1.97 | -17.52% | ― | -100.00% | 20.96% | |
43 Neutral | kr108.08M | -10.66 | -93.01% | ― | ― | 54.60% |
* Healthcare Sector Average
SE:ALZ
Alzinova AB
0.42
-0.70
-62.50%
SE:ALZCUR
AlzeCure Pharma AB
7.76
5.18
200.43%
SE:BIOA.B
BioArctic AB Class B
324.60
38.10
13.30%
SE:SANION
Saniona AB
10.01
-2.01
-16.72%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.73
-1.27
-42.28%
SE:ACTI
Active Biotech AB
4.20
-8.99
-68.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.